In reply: We thank Solvyns and Ralston for their thoughtful and heartfelt comments and their assistance in ensuring historical accuracy regarding the issues surrounding iatrogenic Creutzfeldt–Jakob disease (CJD) risk and recipients of the Australian Human Pituitary Hormone Program (AHPHP).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Boyd A, Klug GMJA, Schonberger LB, et al. Iatrogenic Creutzfeldt–Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients? Med J Aust 2010; 193: 366-369. <eMJA full text> <MJA full text>
- 2. Allars M. Report of the inquiry into the use of pituitary derived hormones in Australia and Creutzfeldt-Jakob disease. Canberra: AGPS, 1994: 630.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
The Australian National Creutzfeldt–Jakob Disease Registry is funded by the Australian Government Department of Health and Ageing. Steven Collins is the Medical Director of the CJD Support Group Network. He receives Fellowship and program grant funding from the National Health and Medical Research Council.